Full text loading...
-
A Case of de novo; Annular-plaque Type Psoriasis Following Oxford- AstraZeneca COVID-19 Vaccination
- Source: Current Drug Safety, Volume 18, Issue 4, Nov 2023, p. 584 - 588
-
- 01 Nov 2023
Abstract
Background: There have been increasing reported cases of new-onset or aggravation of pre-existing dermatoses after the implementation of COVID-19 vaccination. Case Presentation: An elderly male was presented with multiple annular scaly plaques all over the body two weeks following administration of the first dose of Oxford-AstraZeneca COVID-19 vaccine. The lesions further aggravated after taking the second dose of the vaccine. The clinical and histopathology features were suggestive of annular plaque psoriasis. Conclusion: We report this first case of de novo plaque psoriasis following the Oxford- AstraZeneca COVID-19 vaccine, and it signifies a potential side effect of autoimmune reactivation after COVID vaccination.
© Bentham Science Publishers